dehydroepiandrosterone has been researched along with Frigidity in 31 studies
Dehydroepiandrosterone: A major C19 steroid produced by the ADRENAL CORTEX. It is also produced in small quantities in the TESTIS and the OVARY. Dehydroepiandrosterone (DHEA) can be converted to TESTOSTERONE; ANDROSTENEDIONE; ESTRADIOL; and ESTRONE. Most of DHEA is sulfated (DEHYDROEPIANDROSTERONE SULFATE) before secretion.
dehydroepiandrosterone : An androstanoid that is androst-5-ene substituted by a beta-hydroxy group at position 3 and an oxo group at position 17. It is a naturally occurring steroid hormone produced by the adrenal glands.
| Excerpt | Relevance | Reference |
|---|---|---|
| " The pattern of breakthrough bleeding did not substantially differ between the DHEA and PL groups and no significant adverse endometrial effects were apparent." | 2.74 | The safety of 52 weeks of oral DHEA therapy for postmenopausal women. ( Adams, J; Bell, RJ; Davis, SR; Jane, F; Morrow, C; Panjari, M, 2009) |
| "Sexual dysfunction is not a symptom of PTSD but is a common clinical complaint in trauma survivors with this disorder." | 1.43 | Sexual dysfunction and neuroendocrine correlates of posttraumatic stress disorder in combat veterans: Preliminary findings. ( Bierer, LM; Flory, JD; Lehrner, A; Makotkine, I; Marmar, CR; Yehuda, R, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 15 (48.39) | 29.6817 |
| 2010's | 13 (41.94) | 24.3611 |
| 2020's | 3 (9.68) | 2.80 |
| Authors | Studies |
|---|---|
| Nappi, RE | 1 |
| Tiranini, L | 1 |
| Cucinella, L | 1 |
| Martini, E | 1 |
| Bosoni, D | 1 |
| Righi, A | 1 |
| Cassani, C | 1 |
| Gardella, B | 1 |
| Vegunta, S | 1 |
| Kling, JM | 1 |
| Kapoor, E | 1 |
| Basson, R | 4 |
| O'Loughlin, JI | 1 |
| Weinberg, J | 1 |
| Young, AH | 1 |
| Bodnar, T | 1 |
| Brotto, LA | 1 |
| Davis, SR | 4 |
| Hamilton, LD | 1 |
| Meston, CM | 1 |
| Labrie, F | 1 |
| Archer, D | 1 |
| Bouchard, C | 1 |
| Fortier, M | 1 |
| Cusan, L | 1 |
| Gomez, JL | 1 |
| Girard, G | 1 |
| Baron, M | 1 |
| Ayotte, N | 1 |
| Moreau, M | 1 |
| Dubé, R | 1 |
| Côté, I | 1 |
| Labrie, C | 1 |
| Lavoie, L | 1 |
| Gilbert, L | 1 |
| Martel, C | 1 |
| Balser, J | 1 |
| Zimmerman, Y | 1 |
| Foidart, JM | 1 |
| Pintiaux, A | 1 |
| Minon, JM | 1 |
| Fauser, BC | 1 |
| Cobey, K | 1 |
| Coelingh Bennink, HJ | 1 |
| Lehrner, A | 1 |
| Flory, JD | 1 |
| Bierer, LM | 1 |
| Makotkine, I | 1 |
| Marmar, CR | 1 |
| Yehuda, R | 1 |
| Farmer, M | 1 |
| Yoon, H | 1 |
| Goldstein, I | 3 |
| Peixoto, C | 1 |
| Carrilho, CG | 1 |
| Barros, JA | 1 |
| Ribeiro, TT | 1 |
| Silva, LM | 1 |
| Nardi, AE | 1 |
| Cardoso, A | 1 |
| Veras, AB | 1 |
| Kim, NN | 2 |
| Panjari, M | 3 |
| Bell, RJ | 2 |
| Jane, F | 2 |
| Adams, J | 2 |
| Morrow, C | 2 |
| Wolfe, R | 1 |
| Wierman, ME | 1 |
| van Lankveld, J | 1 |
| Brotto, L | 1 |
| DeRogatis, LR | 1 |
| Palacios, S | 1 |
| Stanczyk, FZ | 1 |
| Bloch, M | 1 |
| Meiboom, H | 1 |
| Zaig, I | 1 |
| Schreiber, S | 1 |
| Abramov, L | 1 |
| Shifren, JL | 1 |
| Boone, SA | 1 |
| Shields, KM | 1 |
| Cameron, DR | 1 |
| Braunstein, GD | 1 |
| Johnson, CE | 1 |
| Berman, JR | 1 |
| Mizuno, T | 1 |
| Yotsuyanagi, S | 1 |
| Nagasaka, Y | 1 |
| Namiki, M | 1 |
| Herzog, AG | 1 |
| Drislane, FW | 1 |
| Schomer, DL | 1 |
| Pennell, PB | 1 |
| Bromfield, EB | 1 |
| Dworetzky, BA | 1 |
| Farina, EL | 1 |
| Frye, CA | 1 |
| Bachmann, G | 1 |
| Oza, D | 1 |
| Kuba, R | 1 |
| Pohanka, M | 1 |
| Zákopcan, J | 1 |
| Novotná, I | 1 |
| Rektor, I | 1 |
| Tamler, R | 1 |
| Mechanick, JI | 1 |
| Munarriz, R | 2 |
| Talakoub, L | 2 |
| Flaherty, E | 2 |
| Gioia, M | 2 |
| Hoag, L | 2 |
| Traish, A | 1 |
| Guay, A | 1 |
| Spark, R | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Open-Label Vulvoscopy Photography Study of Changes in Vulva, Vestibule, Urethral Meatus and Vagina 20 Weeks Post Daily Administration of 6.5 Mg Vaginal Prasterone in Menopausal Women With Moderate to Severe Dyspareunia[NCT03568604] | Phase 4 | 18 participants (Actual) | Interventional | 2018-08-07 | Completed | ||
| Topical DHEA Against Vaginal Atrophy (3-Month Placebo-Controlled Double-Blind Randomized Phase III Study)[NCT01846442] | Phase 3 | 218 participants (Actual) | Interventional | 2007-06-30 | Completed | ||
| Effect of Combined Antihypertensive Therapy on Blood Pressure and Sexual Function in Patients With Essential Hypertension[NCT01238705] | Phase 4 | 280 participants (Anticipated) | Interventional | 2008-04-30 | Recruiting | ||
| Dehydroepiandrosterone (DHEA) Treatment in Women and Men Experiencing Hypoactive Sexual Desire Disorder: Modulation of Sexual Libido by Androgens and Neurosteroids[NCT00916396] | 50 participants (Anticipated) | Interventional | 2005-06-30 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
To evaluate the aspect of the vaginal mucosa and the local tolerance to DHEA suppository, the vaginal color (one of the four main signs of vaginal atrophy) evaluated by the physician/gynecologist as corresponding to none, mild, moderate, or severe atrophy was analyzed using the score values of 1, 2, 3 and 4, respectively. Data obtained at Baseline and Week 12 as well as the change from Baseline to Week 12 are presented. (NCT01846442)
Timeframe: Baseline and Week 12
| Intervention | units on a scale (Mean) | ||
|---|---|---|---|
| Baseline | Week 12 | Change from Baseline | |
| 0.25% DHEA | 3.0 | 2.0 | -1.0 |
| 0.50% DHEA | 3.1 | 1.8 | -1.3 |
| 1.00% DHEA | 3.1 | 1.6 | -1.5 |
| Placebo | 3.1 | 2.7 | -0.5 |
To evaluate the aspect of the vaginal mucosa and the local tolerance to DHEA suppository, the vaginal epithelial integrity (one of the four main signs of vaginal atrophy) evaluated by the physician/gynecologist as corresponding to none, mild, moderate, or severe atrophy was analyzed using the score values of 1, 2, 3 and 4, respectively. Data obtained at Baseline and Week 12 as well as the change from Baseline to Week 12 are presented. (NCT01846442)
Timeframe: Baseline and Week 12
| Intervention | units on a scale (Mean) | ||
|---|---|---|---|
| Baseline | Week 12 | Change from Baseline | |
| 0.25% DHEA | 2.7 | 1.7 | -1.0 |
| 0.50% DHEA | 2.8 | 1.5 | -1.3 |
| 1.00% DHEA | 2.7 | 1.4 | -1.3 |
| Placebo | 2.8 | 2.4 | -0.4 |
To evaluate the aspect of the vaginal mucosa and the local tolerance to DHEA suppository, the vaginal epithelial surface thickness(one of the four main signs of vaginal atrophy) evaluated by the physician/gynecologist as corresponding to none, mild, moderate, or severe atrophy was analyzed using the score values of 1, 2, 3 and 4, respectively. Data obtained at Baseline and Week 12 as well as the change from Baseline to Week 12 are presented. (NCT01846442)
Timeframe: Baseline and Week 12
| Intervention | units on a scale (Mean) | ||
|---|---|---|---|
| Baseline | Week 12 | Change from Baseline | |
| 0.25% DHEA | 2.9 | 1.9 | -1.0 |
| 0.50% DHEA | 3.1 | 1.8 | -1.3 |
| 1.00% DHEA | 3.0 | 1.6 | -1.4 |
| Placebo | 3.0 | 2.6 | -0.4 |
To evaluate the aspect of the vaginal mucosa and the local tolerance to DHEA suppository, the vaginal secretions (one of the four main signs of vaginal atrophy) evaluated by the physician/gynecologist as corresponding to none, mild, moderate, or severe atrophy were analyzed using the score values of 1, 2, 3 and 4, respectively. Data obtained at Baseline and Week 12 as well as the change from Baseline to Week 12 are presented. (NCT01846442)
Timeframe: Baseline and Week 12
| Intervention | units on a scale (Mean) | ||
|---|---|---|---|
| Baseline | Week 12 | Change from Baseline | |
| 0.25% DHEA | 3.1 | 1.9 | -1.2 |
| 0.50% DHEA | 3.2 | 1.8 | -1.4 |
| 1.00% DHEA | 3.0 | 1.5 | -1.4 |
| Placebo | 3.1 | 2.7 | -0.4 |
The severity of dyspareunia was evaluated by a questionnaire. The severity of dyspareunia recorded as none, mild, moderate or severe was analyzed using the score values of 0, 1, 2 or 3, respectively. Data obtained at Baseline and Week 12 as well as the change from Baseline to Week 12 are presented. (NCT01846442)
Timeframe: Baseline and Week 12
| Intervention | units on a scale (Mean) | ||
|---|---|---|---|
| Baseline | Week 12 | Change from Baseline | |
| 0.25% DHEA | 2.8 | 1.4 | -1.3 |
| 0.50% DHEA | 2.7 | 1.1 | -1.6 |
| 1.00% DHEA | 2.6 | 1.2 | -1.4 |
| Placebo | 2.8 | 2.3 | -0.4 |
The percentage of parabasal cells was determined from the vaginal smears collected during the study. A 100-cell count was performed by a central laboratory to classify cells as parabasal (P) (including basal), intermediate (I), and superficial (S) squamous cell types. Data obtained at Baseline and Week 12 as well as the change from Baseline to Week 12 are presented. (NCT01846442)
Timeframe: Baseline and Week 12
| Intervention | percentage of parabasal cells (Mean) | ||
|---|---|---|---|
| Baseline | Week 12 | Change from Baseline | |
| 0.25% DHEA | 65.5 | 16.9 | -48.6 |
| 0.50% DHEA | 53.4 | 11.0 | -42.4 |
| 1.00% DHEA | 61.8 | 6.90 | -54.9 |
| Placebo | 46.7 | 47.8 | 1.1 |
The percentage of superficial cells was determined from the vaginal smears collected during the study. A 100-cell count was performed by a central laboratory to classify cells as parabasal (P) (including basal), intermediate (I), and superficial (S) squamous cell types. Data obtained at Baseline and Week 12 as well as the change from Baseline to Week 12 are presented. (NCT01846442)
Timeframe: Baseline and Week 12
| Intervention | percentage of superficial cells (Mean) | ||
|---|---|---|---|
| Baseline | Week 12 | Change from Baseline | |
| 0.25% DHEA | 0.4 | 5.7 | 5.3 |
| 0.50% DHEA | 0.4 | 5.2 | 4.8 |
| 1.00% DHEA | 0.4 | 6.5 | 6.1 |
| Placebo | 0.6 | 0.5 | -0.1 |
A pH strip was applied directly to the lateral wall of the vagina using forceps. The change in color of the pH indicator strip was compared to the color chart for pH evaluation. The corresponding pH value (with one decimal) was recorded. Data obtained at Baseline and Week 12 as well as the change from Baseline to Week 12 are presented. (NCT01846442)
Timeframe: Baseline and Week 12
| Intervention | pH (Mean) | ||
|---|---|---|---|
| Baseline | Week 12 | Change from Baseline | |
| 0.25% DHEA | 6.6 | 5.5 | -1.1 |
| 0.50% DHEA | 6.6 | 5.2 | -1.5 |
| 1.00% DHEA | 6.5 | 5.1 | -1.4 |
| Placebo | 6.5 | 6.0 | -0.5 |
14 reviews available for dehydroepiandrosterone and Frigidity
| Article | Year |
|---|---|
Androgen Therapy in Women.
Topics: Androgens; Dehydroepiandrosterone; Female; Hormone Replacement Therapy; Humans; Libido; Postmenopaus | 2020 |
Sexual Dysfunctions in Women: Are Androgens at Fault?
Topics: Androgens; Dehydroepiandrosterone; Female; Humans; Libido; Sexual Dysfunction, Physiological; Sexual | 2021 |
Androgen use for low sexual desire in midlife women.
Topics: Androgens; Dehydroepiandrosterone; Female; Humans; Menopause; Middle Aged; Sex Hormone-Binding Globu | 2013 |
Future Targets for Female Sexual Dysfunction.
Topics: Alprostadil; Anxiety; Aphrodisiacs; Apomorphine; Consensus; Dehydroepiandrosterone; Dopamine; Dopami | 2016 |
The effects of dehydroepiandrosterone on sexual function: a systematic review.
Topics: Dehydroepiandrosterone; Female; Humans; Libido; Middle Aged; Postmenopause; Quality of Life; Sexual | 2017 |
Sex steroid hormones in diabetes-induced sexual dysfunction: focus on the female gender.
Topics: Clitoris; Dehydroepiandrosterone; Diabetes Mellitus, Type 2; Estrogens; Female; Glucose Intolerance; | 2009 |
Hypoactive Sexual Desire Disorder and current pharmacotherapeutic options in women.
Topics: Adult; Aged; Androgens; Dehydroepiandrosterone; Female; Hormone Replacement Therapy; Humans; Middle | 2011 |
Clinical review: DHEA replacement for postmenopausal women.
Topics: Cognition; Dehydroepiandrosterone; Female; Hormone Replacement Therapy; Humans; Postmenopause; Rando | 2011 |
The role of androgens in female sexual dysfunction.
Topics: Administration, Cutaneous; Administration, Oral; Androgens; Arousal; Chemistry, Pharmaceutical; Clin | 2004 |
The use of dehydroepiandrosterone therapy in clinical practice.
Topics: Adrenal Insufficiency; Aging; Alzheimer Disease; Bone Density; Cardiovascular Diseases; Dehydroepian | 2005 |
The role of androgens in hormone replacement therapy.
Topics: Adult; Age Factors; Aged; Androgens; Breast Neoplasms; Cardiovascular System; Dehydroepiandrosterone | 2005 |
Clinical practice. Sexual desire and arousal disorders in women.
Topics: Combined Modality Therapy; Dehydroepiandrosterone; Estrogens; Female; Humans; Middle Aged; Practice | 2006 |
Female androgen insufficiency.
Topics: Adrenal Glands; Aging; Algorithms; Androgens; Dehydroepiandrosterone; Female; Humans; Libido; Ovarie | 2006 |
Dietary supplements and nutraceuticals in the management of andrologic disorders.
Topics: Antioxidants; Arginine; Carnitine; Dehydroepiandrosterone; Diet; Dietary Supplements; Erectile Dysfu | 2007 |
5 trials available for dehydroepiandrosterone and Frigidity
| Article | Year |
|---|---|
Lack of influence of dyspareunia on the beneficial effect of intravaginal prasterone (dehydroepiandrosterone, DHEA) on sexual dysfunction in postmenopausal women.
Topics: Administration, Intravaginal; Adult; Aged; Androgens; Arousal; Dehydroepiandrosterone; Double-Blind | 2014 |
Lack of influence of dyspareunia on the beneficial effect of intravaginal prasterone (dehydroepiandrosterone, DHEA) on sexual dysfunction in postmenopausal women.
Topics: Administration, Intravaginal; Adult; Aged; Androgens; Arousal; Dehydroepiandrosterone; Double-Blind | 2014 |
Lack of influence of dyspareunia on the beneficial effect of intravaginal prasterone (dehydroepiandrosterone, DHEA) on sexual dysfunction in postmenopausal women.
Topics: Administration, Intravaginal; Adult; Aged; Androgens; Arousal; Dehydroepiandrosterone; Double-Blind | 2014 |
Lack of influence of dyspareunia on the beneficial effect of intravaginal prasterone (dehydroepiandrosterone, DHEA) on sexual dysfunction in postmenopausal women.
Topics: Administration, Intravaginal; Adult; Aged; Androgens; Arousal; Dehydroepiandrosterone; Double-Blind | 2014 |
Restoring testosterone levels by adding dehydroepiandrosterone to a drospirenone containing combined oral contraceptive: II. Clinical effects.
Topics: Acne Vulgaris; Adolescent; Adult; Androgen Antagonists; Androstenes; Belgium; Contraceptives, Oral, | 2015 |
The safety of 52 weeks of oral DHEA therapy for postmenopausal women.
Topics: Administration, Oral; Blood Glucose; Dehydroepiandrosterone; Dose-Response Relationship, Drug; Doubl | 2009 |
A randomized trial of oral DHEA treatment for sexual function, well-being, and menopausal symptoms in postmenopausal women with low libido.
Topics: Adjuvants, Immunologic; Administration, Oral; Adult; Aged; Analysis of Variance; Climacteric; Dehydr | 2009 |
The use of dehydroepiandrosterone in the treatment of hypoactive sexual desire disorder: a report of gender differences.
Topics: Adult; Aged; Androsterone; Biotransformation; Dehydroepiandrosterone; Dehydroepiandrosterone Sulfate | 2013 |
12 other studies available for dehydroepiandrosterone and Frigidity
| Article | Year |
|---|---|
Pharmacotherapy for female sexual dysfunctions (FSDs): what is on the market and where is this field heading?
Topics: Dehydroepiandrosterone; Female; Humans; Premenopause; Quality of Life; Sexual Behavior; Sexual Dysfu | 2023 |
Dehydroepiandrosterone and cortisol as markers of HPA axis dysregulation in women with low sexual desire.
Topics: Adult; Biomarkers; Circadian Rhythm; Dehydroepiandrosterone; Female; Humans; Hydrocortisone; Hypotha | 2019 |
Chronic stress and sexual function in women.
Topics: Adult; Arousal; Attention; Chronic Disease; Cognition; Dehydroepiandrosterone; Erotica; Female; Geni | 2013 |
Sexual dysfunction and neuroendocrine correlates of posttraumatic stress disorder in combat veterans: Preliminary findings.
Topics: Adult; Combat Disorders; Comorbidity; Cross-Sectional Studies; Dehydroepiandrosterone; Depressive Di | 2016 |
Summary of the recommendations on sexual dysfunctions in women.
Topics: Adjuvants, Immunologic; Dehydroepiandrosterone; Diagnostic and Statistical Manual of Mental Disorder | 2010 |
Consultation corner. The latest on female sexual health.
Topics: Adjuvants, Immunologic; Adult; Antidepressive Agents, Second-Generation; Atrophy; Benzimidazoles; Bu | 2010 |
Dietary supplements for female sexual dysfunction.
Topics: Adjuvants, Immunologic; Adult; Aged; Complementary Therapies; Dehydroepiandrosterone; Double-Blind M | 2005 |
Dehydroepiandrosterone alleviates copulatory disorder induced by social stress in male rats.
Topics: Animals; Copulation; Dehydroepiandrosterone; Disease Models, Animal; Ejaculation; Rats; Rats, Spragu | 2006 |
Differential effects of antiepileptic drugs on neuroactive steroids in men with epilepsy.
Topics: Adolescent; Adult; Androgens; Androstanes; Anticonvulsants; Biological Availability; Carbamazepine; | 2006 |
Sexual dysfunctions and blood hormonal profile in men with focal epilepsy.
Topics: Adolescent; Adult; Androgens; Comorbidity; Dehydroepiandrosterone; Epilepsies, Partial; Erectile Dys | 2006 |
Androgen replacement therapy with dehydroepiandrosterone for androgen insufficiency and female sexual dysfunction: androgen and questionnaire results.
Topics: Adjuvants, Immunologic; Adult; Androgens; Dehydroepiandrosterone; Female; Hormone Replacement Therap | 2002 |
Epidemiological characteristics of 250 women with sexual dysfunction who presented for initial evaluation.
Topics: Adult; Dehydroepiandrosterone; Female; Humans; Middle Aged; Sexual Dysfunctions, Psychological; Surv | 2002 |